Macrocyclic lactone resistance in Dirofilaria immitis: risks for prevention of heartworm disease

Roger K Prichard1

  • 1Institute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte Anne-de-Bellevue, Quebec H9X 3V9, Canada.

Insights

Heartworm resistance in pets is a growing concern, with macrocyclic lactones losing efficacy. New preventive strategies and diagnostic tools are crucial to combat this lethal disease and protect canine and feline health.

Area of Science:

  • Veterinary Parasitology
  • Drug Resistance Studies
  • Companion Animal Health

Background:

  • Heartworm disease (caused by Dirofilaria immitis) is a significant, potentially lethal threat to dogs and cats globally.
  • Macrocyclic lactones are the primary class of drugs used for heartworm prevention, administered regularly.
  • Emerging resistance of Dirofilaria immitis to macrocyclic lactones has been documented, compromising prevention efficacy.

Purpose of the Study:

  • To discuss factors contributing to the development of macrocyclic lactone resistance in heartworm.
  • To highlight the need for improved diagnostic methods to confirm heartworm resistance.
  • To explore alternative and complementary strategies for heartworm prevention and control.

Main Methods:

  • Review and discussion of factors influencing resistance development.
  • Evaluation of current and potential diagnostic tests for resistance (in vivo, microfilariae suppression, DNA markers).
  • Consideration of complementary control methods like repellents, insecticides, and anti-Wolbachia treatments.

Main Results:

  • Macrocyclic lactone resistance is a confirmed issue, necessitating a deeper understanding of its drivers.
  • Current methods for confirming resistance are often expensive, slow, or ethically challenging.
  • While new strategies like doxycycline and long-acting injectables show promise, new preventive classes are urgently needed.

Conclusions:

  • Continued reliance on failing macrocyclic lactones will exacerbate resistance and disease spread.
  • Development of novel heartworm preventives is critical, though regulatory hurdles for 100% efficacy may impede progress.
  • Integrated approaches combining new preventives, diagnostics, and vector control are essential for sustainable heartworm management.

Related Concept Videos

Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...